17 April 2026

BSF Enterprise PLC

Admission of Placing Shares

Further to the announcement published on 02 April 2026, BSF Enterprise PLC ("BSF" or the "Company"), a leading innovator in tissue-engineered materials, announces that 38,500,000 ordinary shares of £0.01 each in the issued share capital of the Company ("April 2026 Placing Shares") have been admitted yesterday, 16 April 2026, to trading on the Main Market of the London Stock Exchange.

April 2025 Placing - admission update

Further to the announcement published on 28 April 2025 in relation to the placing of 4,725,000 new ordinary shares in the Company at 3 pence per share (the "April 2025 Placing Shares"), the Company has instructed new advisers, Bowsprit Partners, to arrange the application for the April 2025 Placing Shares to be admitted to listing on the Official List and to trading on the Main Market of the London Stock Exchange ("Admission").

The April 2025 Placing Shares were issued on 15 May 2025 pursuant to the placing announced on 28 April 2025. It is expected that Admission will become effective and that dealings in those shares are expected to commence at 8.00 a.m. on 21 April 2026.

Correction to Broker Warrants disclosure

The Company corrects an error in its announcement of 2 April 2026. The number of Broker Warrants was stated as 23,100. The correct number is 2,310,000.

Total voting rights

Following Admission, the total number of ordinary shares and voting rights in the Company will be 166,874,437. The total number of ordinary shares in issue is unchanged from the announcement dated 2 April 2026, as the April 2025 Placing Shares were already issued and included in that figure.

This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of Regulation 2014/596/EU which is part of domestic UK law pursuant to the Market Abuse (Amendment) (EU Exit) regulations (SI 2019/310).

END

Engage with the BSF Enterprise management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor website here:

 https://bsfenterprise.com/link/y0zqZr

 For further enquiries, please visit www.bsfenterprise.com or contact:

Subscribe to our news alert service: https://bsfenterprise.com/s/bb9f43

About BSF Enterprise PLC

BSF Enterprise PLC (LSE:BSFA) develops and commercialises cutting-edge tissue-engineered solutions, including lab-grown leather (via LGL), cultivated meat, and corneal repair technologies. By leveraging its proprietary scaffold-free ATEP™ platform, BSF delivers sustainable, high-performance alternatives to conventional materials, targeting global markets where provenance, ethics, and performance are increasingly prized by consumers and brands alike.